S527-119

Reported

To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.

119th Congress Introduced Feb 11, 2025

Legislative Progress

Reported
Introduced Committee Passed
Apr 10, 2025

Reported by Mr. Grassley, without amendment

Feb 11, 2025

Mr. Grassley (for himself, Ms. Cantwell, Mr. Marshall, Mr. Welch, …

Feb 11, 2025

Mr. Grassley (for himself, Ms. Cantwell, Mr. Marshall, Mr. Welch, …

Summary

What This Bill Does

Directs the FTC to study and report on pharmacy benefit managers (PBMs) pricing practices, vertical integration, and impact on drug costs. Examines whether PBMs steer patients to affiliated pharmacies or manipulate formularies.

Who Benefits and How

  • Congress receives comprehensive analysis of PBM practices
  • Consumers and payers may gain transparency on drug pricing intermediaries
  • Independent pharmacies may benefit if study reveals anticompetitive practices

Who Bears the Burden and How

  • FTC must conduct comprehensive study within 1 year
  • PBMs face scrutiny of pricing, audit, and steering practices
  • Healthcare intermediaries subject to competition analysis

Key Provisions

  • Study whether PBMs charge payers more than they reimburse pharmacies
  • Examine patient steering to PBM-owned pharmacies
  • Analyze use of proprietary pharmacy data for competitive advantage
  • Assess formulary designs effect on drug costs
Model: claude-opus-4
Generated: Jan 10, 2026 17:11

Evidence Chain:

This summary is derived from the structured analysis below. See "Detailed Analysis" for per-title beneficiaries/burden bearers with clause-level evidence links.

Primary Purpose

Requires FTC study of pharmacy benefit managers and pharmaceutical supply chain intermediaries

Policy Domains

Healthcare Antitrust Drug Pricing

Legislative Strategy

"Build evidence base for potential PBM regulation through FTC study"

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Antitrust
Actor Mappings
"the_commission"
→ Federal Trade Commission

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology